Chinese obesity may become a rival to Eli Lilly’s Zepbound

A version of this article was first published in the CNBC’s healthy return bulletin, which brought the latest health news directly to your box. Subscribe here To get future prints.

Another potential competitor other than obesity treatments breaking box office records Hand Lilly And Novo Nordisk He just showed positive data – but this time from China.

Chinese drug producer Hengrui Pharma and an experimental week -week injection developed by US -based partner Kailera Therapeutics late stage attempt In China, he put drug producers in his way to get approval there.

Kailera is among the various companies such as Merck, Novo Nordisk and Regenon, touching the Chinese market in search of a drug that can gain a tranche of the drug market. Kailera in May 2024 licensed Apart from the Great Chinese region, more than $ 100 million in Hengrui, pre -and near -term payments, 20% equity shares and rights for more than one experimental drugs for approximately $ 6 billion on future milestones.

The so -called HRS9531, which was performed in the experiment, helped to lose about 18% of its average body weight after 48 weeks, which is more than 16% loss of weight loss than placebo saws.

Approximately 9 out of 10 people who injected have lost at least 5% of the body weight and 44.4% of the patients gained at least 20% weight loss according to a release of companies. There was no plateau with weight loss in 48 weeks.

Companies did not explain how well the patient’s specific safety data or the drug tolerates the drug, just saying that these results are consistent with previous data on treatment and other GLP-1s. Companies, negative events from the injection, associated with gastrointestinal and moderately serious, he said.

Hengrui will apply for a approval for drugs in China. Meanwhile, Kailera said that he will start global studies using higher doses and patients who have been treated for longer patients.

It will still take a few years for HRS9531 to enter the market, especially in other countries other than the USA and China. However, the results of the drug seem promising, and Eli positions it as a potential opponent for Lilly’s weekly weight loss injection.

Both drugs work by activating two hormones produced naturally in the body: glucagon-like peptide-1, GLP-1 and glucose-induced insulinotropic polypeptide or gIP. It is said that the combination slows down the emptying of the stomach, slowing down the hunger signals in the brain and suppressing the appetite for a longer time and suppressing the appetite.

In the two stages of approximately 3,000 adults with obesity or type 2 diabetes, Zepbound helps patients to lose average. Up to 21% of body weight More than 72 weeks.

Especially since the last results in HRS9531 are only more than 500 patients, it is difficult to compare the results from different clinical studies. However, the drug still gained significant weight loss for 48 weeks and increased hopes about its potential for a longer time.

Meanwhile, wegovy wegovy of Novo Nordisk’s weekly injection is only targeting the GLP-1.

Feel free to send any clues, suggestions, story ideas and data to Annika. Annikakim.constantino@nbcuni.com.

Well, after a long epic, mother wojcicki Officially won Embatted genetic test company 23andme.

Wojcicki founded 23andme and the company served as CEO until he applied for 11 bankruptcy protection in March. In a statement on Monday, the company has completed the acquisition of personal genome service and research services business lines.

“As a part of TTAM, 23andme continues to provide personalized DNA tests and research services to customers,” the company says. He said. “TTAM is determined to provide selection and transparency to customers, including the option to change their decisions that they will not participate in the research.”

TTAM is the abbreviation of the first letters of 23andme. Wall Street Journal.

23Andme has become the main current with DNA test kits in the house, which provides information to customers about family history and genetic profiles. However, five times the CNBC Disruptor 50 companies have fought to support repeated revenue and support applicable research and therapeutic businesses after opening to the public.

When it was understood that the financial financials of 23Andme were shaky, Wojcicki presented various offers to get the company private, while the company was still a general manager. These plans failed and eventually had to compete against other possible buyers in the bankruptcy auction.

And of course, there were some unexpected bending.

In May, Regeneneron Pharmaceuticals announced that after the bankruptcy auction, 23Andme will buy most of its assets for $ 256 million. However, Wojcicki offered a separate bid of $ 305 million through TTAM and forced it to reopen the auction.

A month later, he did this, and TTAM announced that he successfully left Regeneron.

“I am very excited to continue the duties of 23andme to help people access, understand and benefit people to reach the human genome of the TTAM Research Institute,” Wojcicki said in June. He said.

Feel free to send any clues, suggestions, story ideas and data to Ashley at Ashley.capoot@nbcuni.com.